Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 - a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke

Research output: Contribution to journalJournal articleResearchpeer-review


  • Patrick Sulzgruber
  • Sven Wassmann
  • Anne Grete Semb
  • Wolfram Doehner
  • Petr Widimsky
  • Thomas Gremmel
  • Juan Carlos Kaski
  • Gianluigi Savarese
  • Giuseppe M C Rosano
  • Claudio Borghi
  • Keld Kjeldsen
  • Christian Torp-Pedersen
  • Thomas Andersen Schmidt
  • Basil S Lewis
  • Heinz Drexel
  • Juan Tamargo
  • Dan Atar
  • Stefan Agewall
  • Alexander Niessner
View graph of relations

Oral anticoagulation in patients presenting with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 (CHA2DS2-VASc of 2 in women) remains a challenging approach in clinical practice. Therapeutic decisions need to balance the individual benefit of reducing thromboembolic risk against the potential harm due to an increase in bleeding risk in this intermediate risk patient population. Within the current opinion statement of the European Society of Cardiology working group of cardiovascular pharmacotherapy and the European Society of Cardiology council on stroke the currently available evidence on the anti-thrombotic management in patients presenting with a CHA2DS2-VASc of 1 is summarized. Easily applicable tools for a personalized refinement of the individual thromboembolic risk in patients with atrial fibrillation and a CHA2DS2-VASc score of 1 that guide clinicians through the question whether to anticoagulate or not are provided.

Original languageEnglish
Article numberpvz016
JournalEuropean heart journal. Cardiovascular pharmacotherapy
Issue number3
Pages (from-to)171-180
Number of pages10
Publication statusPublished - 1 Jul 2019

Bibliographical note

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email:

    Research areas

  • Anticoagulation, Atrial fibrillation, CHA DS -VASc score, Intermediate risk

ID: 57230123